ESMO25: Harnessing the innate and the adaptive immune response, with Dr Sandeep Reddy
Oncology
As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.
Dr Reddy discussed the importance of FDA Expanded Access authorisation for its Cancer BioShield platform, anchored by ANKTIVA, as well as the surge of innovation happening in the non–muscle invasive bladder cancer (NMIBC) space at the moment, and oncological developments explored across the Congress as a whole.
Watch this and other conversations from ESMO 2025 here.
